· Dresden 2006 - Vom Nihilismus zum Algorithmus ·

Lebensqualität bei Patienten mit myelodysplastischen Syndromen

Literatur | Vortrag siehe hier

Autor: Priv.-Doz. Dr. med. Ulrich Schuler, Universitätsklinikum Carl Gustav Carus, Dresden

Quellenangabe: Deutsches MDS-Forum - Dresden 2006

Stand: 27.11.2006

Thomas ML, Heptinstal K, Hassan A.
The Impact of Myelodysplastic Syndromes on Patients' Lives.
Blood [106 (supplement)]. 2005
Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzara A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC.
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
Ann Hematol 2005;84:167-176. PM:15592833
[Medline]
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-MacDonald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Br J Haematol 2003;120:1037-1046. PM:12648074
[Medline]
Thomas ML, Kim H, Miller K, Rowel J, Tallman M, Houston J, Van der Jagt R, Greenberg P, Cella D.
The use of erythropoietin inmyelodysplastic syndromes (MDS): Impact on fatigue and quality of life.
Leuk Res Suppl 2005;29:52-Abstract p75.
Aaronson NK, Bullinger M, Ahmedzai S.
A modular approach to quality-of-life assessment in cancer clinical trials.
Recent Results Cancer Res 1988;111:231-249. PM:2459750
[Medline]
Ware JE, Jr., Sherbourne CD.
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
Med Care 1992;30:473-483. PM:1593914
[Medline]
Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC.
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
J Clin Oncol 2002;20:2441-2452. PM:12011121
[Medline]
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP.
Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2006. PM:16882708
[Medline]
List AF, Dewald G, Bennett J, Giagounidis AA, Raza A, Feldman EJ, Powell BL, Greenberg P, Zeldis J, Knight R.
Hematologic and Cytogenetic (CTG) Response to Lenalidomide (CC-5013) in Patients with Transfusion-Dependent (TD) Myelodysplastic Syndrome (MDS) and Chromosome 5q31.1 Deletion: Results of the Multicenter MDS-003 Study.
J.Clin.Oncol. 2005; 23 (Suplement), abstract #5. 15-5-2005.
Thomas ML, Heptinstal K, Hassan A.
The Importance of the Patient-Physician Relationship in Myelodysplastic Syndromes. Blood [106 (Supplement): ], Abstract 1340. 2005.